You are currently viewing Z-SEASIDE: resolute Zotarolimus-eluting vs Sirolimus- or Everolimus- eluting stent for treatment of bifurcated lesions

Z-SEASIDE: resolute Zotarolimus-eluting vs Sirolimus- or Everolimus- eluting stent for treatment of bifurcated lesions

EBC - ON DEMAND

Z-SEASIDE: resolute Zotarolimus-eluting vs Sirolimus- or Everolimus- eluting stent for treatment of bifurcated lesions

European Bifurcation Club 2010 – EBC 2010 – Budapest, Hungary

New DES and bifurcation stenting

Z-SEASIDE: resolute Zotarolimus-eluting vs Sirolimus- or Everolimus- eluting stent for treatment of bifurcated lesions

Author: Francesco Burzotta, Institute of Cardiology, Catholic University of the Sacred Heart, Rome – Italy

 

BACKGROUND

  • Provisional stenting with drug-eluting stents (DES) is the gold standard for treatment of coronary bifurcated lesions
  • Different DES platforms have remarkable differences which may influence the procedural performance and post-PCI angiographic results
  • Thus, head to head comparisons of different DES in bifurcated lesions may be clinically useful

CONCLUSION

In unselected patients with bifurcated lesionsundergoing DES implantation according to a “provisional-TAP” strategy…

  • the procedural outcome may be influenced by DES selection (Z-RES better than SES for “SB troubles”)
  • the acute angiographic result in the SB ostium maybe influenced by DES selection (Z-RES and EES better than SES for SB ostium diameter / area)
  • the 12-month clinical outcome is good using the 3 DES (very low adverse event rate observed with Z-RES deserves more investigations)

 

Download here

Leave a Reply